Search results for: Multi-Indication Medicines
Filter search results
Gundo Weiler
22 June 2026
…Europe, Africa and Asia to develop integrated approaches to health, development and emergencies. Prior to joining the Regional Office for Europe, Gundo served in multiple roles in WHO’s Western Pacific…
World EPA Congress 2027
2 March 2027, 9:00am
World Evidence, Pricing and Access Congress is Europe’s largest conference in market access, pricing and evidence featuring 300 speakers, multiple streams and over 1500 attendees from pharma, biotech and Payers/HTAs….
Can the US Afford to Ignore Cost-Effectiveness Evidence in Health Care?
23 July 2013, 11:00pm
…Dr Chambers noted whether its coverage decisions for medicines are consistent with cost-effectiveness evidence. He also discussed the potential benefits of including economic evidence in Medicare coverage policy in terms…
Uncertainty and Risk in Decision Making
16 July 2014, 11:00pm
…of Economics, providing an academic perspective Andrew Walker from the University of Glasgow/Scottish Medicines Consortium, providing the perspective of an advisor and observer of decision makers. Adrian Towse is the Director…
The Role of Unmet Need in Pharmaceutical Innovation
19 October 2021, 11:00pm
…decisions and in societal assessments of the value of innovative medicines. However, how this critical concept is understood and operationalised is often inconsistent across different points of the development pathway…
OHE Lunchtime Seminar on Pricing
15 April 2010
…biotechnology industries, consultancies, physicians’ associations, and government. The discussion focussed on value-based pricing for prescription medicines in both market and regulated systems, with comparisons of Sweden and the United States….
EU Approval of Biosimilars
8 July 2010
…and summarises the remarks of Dr. Gopalan Narayanan of the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Biosimilar products in the European Union (EU) must go through a centralised procedure that licenses…
Defining Benefit Through Willingness to Pay
24 August 2010
…about the pricing and reimbursement of prescription medicines. Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost…
OHE Consulting: Local and Global Expertise
14 September 2010
…value of global private-public partnerships; some are country specific, such as competition in the NHS; others are sector specific, such as the relationship between spending on medicines and overall efficiency…